Leading from the front, compact management structure, commitment to quality, adoption of latest technologies & revolutionary employee engagement policies have been the foundation of our continuous success.
Making way from Punjab to become one of the most trusted brands in agro-chemical companies, Safex has expanded many folds. We have increased our turnover 13 times and operating profit 17 times in the last 10 years. Yet, we continue to grow while embracing new challenges, expanding boundaries and creating new opportunities.
With business spanning 17 states, Safex today is a 500+ crore company having a dealer count of more than 10,000 providing employment to 1000+ members. Hence, Safex is a pioneer at implementing management principles with utmost sincerity to get the best possible outcomes.
At the core of our progress is our motto: Let’s fly together

ChrysCapital

Established in 1999, ChrysCapital is a leading India focused investment firm, managing approximately $4 billion across eight funds. With over 90 investments since 1999, the group has valuable experience investing across a breadth of sectors. ChrysCapital has developed a strong track record, delivering over $5.5 billion from over 70 exits. The ChrysCapital funds are ranked in the top decile of global private equity funds of similar vintage. ChrysCapital VIII, LLC is the eighth fund of the group that was raised in late 2018 with a corpus of over $850 million.

ChrysCapital believes that partnerships with excellent management teams in attractive sectors are the foundation of successful private equity investing. The integrity and execution capability of management are the two most important factors in the evaluation of an investment opportunity. Our aim is to be a trustworthy financial partner and a stable long-term investor leveraging our deep relationships in the industry.

One of the factors that differentiates ChrysCapital is the ability to scout and help its portfolio companies think through M&A targets. ChrysCapital played an instrumental role in Intas’ $770 mn acquisition of Actavis UK / Ireland. ChrysCapital got Intas into the acquisition process, leveraged industry expertise and relationship with founders to convince them to pursue the acquisition and eventually helped win the deal for Intas. This was the 2nd largest outbound acquisition by an Indian pharma company and propelled them to become the second largest generics player in the UK.

Another differentiating factor is ChrysCapital’s industry leading track record, amongst private equity peers, of assisting portfolio companies to go public through an IPO – ChrysCapital has taken 10 companies public such as AU Small Finance Bank, Eris Lifesciences, Redington, M&M Financial Services, to name a few, and has provided valuable inputs to each of these in their IPO journey as well as in their new life as a publicly-listed company.